US EditionAviadoBio Begins Phase I/II Trial of FTD-GRN Gene Therapy in the UK
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
AviadoBio begins Phase I/II trial of FTD-GRN gene therapy in the UK
AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate AVB-101.The post AviadoBio begins Phase I/II trial of FTD-GRN gene therapy in the UK appeared first on Clinical Trials Arena.
Europe-Wide Gene Therapy Trial Being Delivered In Cardiff
Share Post Share Email A groundbreaking Europe-wide gene therapy trial, delivered in Wales by the Advanced Neurotherapies Centre, funded by Health and Care Research Wales, could potentially stop the progression of frontotemporal dementia (FTD) with a single procedure. Patients across the continent are being recruited to the ASPIRE-FTD trial, which will be delivered at Cardiff and Vale University Health Board. T…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
